Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lonza Won’t Compete With Partners In Teva Biosimilars Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss firm sees potential to earn $500 million to $750 million annually in follow-on biologics market.

You may also be interested in...

Teva Adds To Biosimilars Capabilities Through Partnership With Lonza

Israeli generic giant, Swiss CMO announce joint venture to co-develop, manufacture and market biosimilars.

Merck Announces Major FOB Initiative With Its New Business Unit

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

Medarex/BMS Working To Shift Ipilimumab Trial Endpoint

Overall survival is more valid than freedom from progression in Phase III melanoma trial, firm says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts